Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2007

View Archived Issues

CHF-1512 effective in fluctuating Parkinson's disease

Recent patents disclose novel antidiabetic agents

Sirion raises financing to advance pipeline

New agents for treating Alzheimer's disease imparted in recent Pfizer patent

WAY-258131, a novel BACE-1 inhibitor with in vivo activity in mouse models of Alzheimer's disease

Studies support use of doripenem in urinary tract, intra-abdominal infections

PZ-601 pharmacokinetics assessed in healthy male volunteers

Hepatitis B surface antigen/1018-ISS combination shows promise

Selective beta3-adrenoceptor agonists with reduced cardiac side effects reported by Lilly

Endo receives notices from Anesiva regarding Zingo

AEE-788 inhibits human hepatocellular carcinoma in vitro and in vivo

Ditropan to be reviewed by FDA

sanofi-aventis reports novel therapeutic agents for renal disorders

FDA Arthritis Advisory Committee meets to discuss Arcoxia

Cryptopharma selects CP-92 for development in cystic fibrosis

Repligen licenses Friedreich's ataxia compounds from Scripps Institute

Xyotax has fast track designation for PS2 women with advanced NSCLC

Extended release formulation of the 5-HT1A antagonist AV-965 well tolerated in phase I trials

Rigel updates R-788 program

FDA extends review for eprodisate NDA

Pro-Pharmaceuticals receives FDA letter regarding Davanat/5-FU NDA

ADX-48621 begins phase I for depression, anxiety disorder and pain

New phase IIb study of pafuramidine maleate for malaria

Preliminary phase IIa findings for IPL-455903

Lpath closes first tranche of equity financing

EGIS-1150 effectively controls positive and negative schizophrenia symptoms in vivo

New data indicate higher virologic response with celgosivir combination therapy

Altabax approved for topical treatment of impetigo

Eisai withdraws European application for Aricept in severe Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...